• DOI:10.1097/MJT.0b013e318209e006
• Corpus ID: 14542259

Efficacy and Safety of Two Polyherbal Combinations: E-MA-H and E-MA-HP in Male Sexual Dysfunction

@article{Kulkarni2011EfficacyAS,
  title={Efficacy and Safety of Two Polyherbal Combinations: E-MA-H and E-MA-HP in Male Sexual Dysfunction},
  author={Mugdha Kulkarni and Bhakti S Shinde and Manoj Kumar V. Chaudhari and Ganesh Avhad and Shrikant V Pensalwar and B S V Prasad and Manoj Kumar M. Deshpande and Richard A Rosenbloom},
  journal={American Journal of Therapeutics},
  year={2011},
  volume={18},
  pages={162-169}
}

• M. Kulkarni, Bhakti S Shinde, +5 authors R. Rosenbloom
• Published 1 March 2011
• Medicine
• American Journal of Therapeutics

Efficacy and safety of 2 herbal products-E-MA-H at 2 dose levels, low (HLD) and high (HHD), and E-MA-HP (HP) capsules-versus placebo (PL) was evaluated in subjects with male sexual dysfunction. Males aged 21-60 with erectile dysfunction, premature ejaculation, or other form of sexual dysfunction were studied in this triple-blind, randomized, placebo-controlled, parallel-groups trial. Subjects received any one of the following 4 interventions: E-MA-H 2 capsules at night (HLD) for 60 days; E-MA-H 2 capsules twice daily for 30 days, followed by 2 capsules at night for 30 days (HHD); E-MA-HP (HP) 2 capsules twice daily for 60 days; or placebo (PL) 2 capsules twice daily for 60 days. All dosage regimens were standardized to 2 capsules twice daily by using 2 matching placebo capsules as the morning dose for HLD and on days 31-60 for HHD. Efficacy outcome measures were the international index of erectile function; index for premature ejaculation; erectile dysfunction inventory of treatment satisfaction; subjects' and investigators' global assessment. Safety was assessed through adverse events; hematology; blood chemistry. Of 148 subjects enrolled, 1 was excluded from analysis; data on the intention-to-treat population of 147 (PL = 36, HLD = 38, HHD = 37, HP = 36) were analyzed. There was a significant (P < 0.01) increase in the total international index of erectile function score (mean ± SEM) in subjects receiving HLD (16.28 ± 1.39), HHD (15.40 ± 1.22), and HP (18.55 ± 1.36) compared with PL (6.83 ± 1.52). The same pattern was seen with increase in index for premature ejaculation scores: HLD (9.68 ± 1.17), HHD (10.27 ± 1.05), HP (11.36 ± 1.20) versus PL (3.77 ± 1.04). There was no significant difference in effect among the active treatment groups. The incidence of adverse events was similar in all the groups. Laboratory evaluations did not show any clinically significant abnormality in any of the groups. Treatment with HLD, HHD, and HP is well tolerated, and more effective than placebo (P < 0.01), in subjects with erectile dysfunction, premature ejaculation, and other forms of sexual dysfunction.